Literature DB >> 9766756

Differential adhesiveness between blood and marrow leukemic cells having similar pattern of VLA adhesion molecule expression.

X Thomas1, B Anglaret, M Bailly, O Maritaz, J P Magaud, E Archimbaud.   

Abstract

Functional adhesion of blood and marrow leukemic cells from 14 acute myeloid leukemia patients presenting with hyperleukocytosis was evaluated by performing cytoadhesion assays on purified (extracellular matrix proteins) and non-purified supports (MRC5 fibroblastic cell line). Results, in 30-min chromium release assay, show a mean +/- S.D. adhesion to fibronectin, collagen, and laminin respectively of 30 +/- 17%, 20 +/- 13%, 25 +/- 17% for blood leukemic cells and 18 +/- 11%, 11 +/- 10%, 11 +/- 8% for marrow leukemic cells. These differences between blood and marrow cells were statistically significant (respectively P = 0.005, P = 0.01 and P = 0.002), while no difference was noted regarding adhesion to non-purified supports. The higher adhesion of blood blast cells to purified supports was observed regardless of CD34 expression. No significant difference was observed in the expression of cell surface VLA-molecules (CD29, CD49b, CD49d, CD49e, CD49f) between blood and marrow blast cells. The addition of GM-CSF or G-CSF induced increased adhesion of marrow blasts and decreased adhesion of blood blasts leading to a loss of the difference between blood and marrow cells. In a 60-min chromium release assay, marrow blasts adhered even more than blood leukemic cells to fibronectin. In contrast, marrow blasts from 'aleukemic' acute myeloid leukemia patients did not show any modification regarding their adhesion to extracellular matrix proteins when co-cultured with growth factors.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9766756     DOI: 10.1016/s0145-2126(98)00103-9

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  2 in total

Review 1.  Anti-COVID-19 potential of Azadirachta indica (Neem) leaf extract.

Authors:  Michael O Eze; Chukwunonso E C C Ejike; Patrick Ifeonu; Iroka J Udeinya; Chibuike C Udenigwe; Peter N Uzoegwu
Journal:  Sci Afr       Date:  2022-04-08

2.  The PI3Kδ Inhibitor Idelalisib Inhibits Homing in an in Vitro and in Vivo Model of B ALL.

Authors:  Etai Adam; Hye Na Kim; Eun Ji Gang; Caitlin Schnair; Solomon Lee; Solah Lee; Sajad Khazal; Osanna Kosoyan; Marina Konopleva; Chintan Parekh; Deepa Bhojwani; Alan S Wayne; Hisham Abdel-Azim; Nora Heisterkamp; Yong-Mi Kim
Journal:  Cancers (Basel)       Date:  2017-09-10       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.